Topic: Blue Chip Stocks

Research spending pays off for Pfizer

PFIZER INC. $34 (New York symbol PFE; Income Portfolio, Manufacturing & Industry sector; Shares outstanding: 6.0 billion; Market cap: $204.0 billion; Price-to-sales ratio: 3.8; Dividend yield: 3.8%; TSINetwork Rating: Above Average; www.pfizer.com) is one of the world’s leading prescription drugmakers. Its top-selling brands include Lyrica (epilepsy), Celebrex (arthritis pain), Prevnar (pneumonia) and Enbrel (rheumatoid arthritis).

The company is also a leading maker of over-the-counter treatments, including Advil (pain relief), Centrum (vitamins) and Robitussin (cough syrup).

Pfizer’s revenue fell 17.2%, from $59.0 billion in 2011 to $48.9 billion in 2015. That decline was mainly due to the sale of its nutrition division, which makes formula and other products for children. As well, the company continues to face more competition from generic drugs as many of its main products lose their patent protection.

New businesses help replace older drugs

To counter that, the company continues to buy smaller drugmakers with promising products. In September 2015, it paid $17 billion for Hospira. It makes close copies of biologic drugs that have lost their patent protection.

In 2016, Pfizer paid $14 billion for Medivation. That firm makes Xtandi, a treatment for prostate cancer. The drug’s annual sales could rise from $2.1 billion in 2016 to $5 billion in 2020.

Thanks to those acquisitions, Pfizer’s revenue in 2016 rose 8.1% to $52.8 billion.

Earnings rose 19.5%, from $9.5 billion in 2012 to $11.3 billion in 2013. Earnings per share jumped 31.0%, from $1.26 to $1.65, on fewer shares outstanding. Pfizer’s earnings then fell to $1.41 a share (or a total of $9.1 billion) in 2014, and to $1.11 a share (or $6.9 billion) in 2015. Earnings rebounded to $1.17 a share (or $7.2 billion) in 2016.

If you exclude unusual items, earnings per share rose 9.1%, to $2.40 in 2016 from $2.20 in 2015.

Research continues to play a big role

In addition to acquisitions, Pfizer continues to invest heavily in the development of new drugs. It spent $7.9 billion (or 14.9% of revenue) on research in 2016. That’s up 2.4% from the $7.7 billion (or 15.7% of revenue) in 2015.

Among its recent successes is Xeljanx, a rheumatoid arthritis treatment. Sales of that drug jumped 78% in 2016.

Pfizer’s strong balance sheet will let it continue to invest in its operations. As of December 31, 2016, its long-term debt was $31.4 billion, or just 15% of its market cap. It also held cash of $17.9 billion, or $2.94 a share.

Share buybacks should help boost stock price

The company also uses its cash to buy back shares: in 2016, it spent $5.0 billion on share repurchases. In February 2017, it agreed to buy back an additional $5.0 billion in shares. Recently, Pfizer also increased its dividend by 6.7%. The new annual rate of $1.28 yields 3.8%.

The company expects to earn between $2.50 and $2.60 a share in 2017. The stock trades at a low 13.3 times the midpoint of that range.

Pfizer is a buy.

Comments

Tell Us What YOU Think

You must be logged in to post a comment.

Please be respectful with your comments and help us keep this an area that everyone can enjoy. If you believe a comment is abusive or otherwise violates our Terms of Use, please click here to report it to the administrator.